Adjuvant therapy in operable pancreatic cancer

M. N. Wente; P. Büchler; H. Friess; M. W. Büchler

doi:10.1024/1023-9332.8.2.74

Adjuvant therapy in operable pancreatic cancer

M. N. Wente, P. Büchler, H. Friess, M. W. Büchler

Heidelberg University

Research output: Contribution to journal › Article › peer-review

Abstract

Adenocarcinoma of the pancreas remains a highly lethal disease with one of the worst mean survival rates of all solid malignancies. Even with improvements in surgical techniques in the last decades, the five-year survival rate of patients following resection is still under 20 percent. Various additional treatment concepts have been introduced based on encouraging results for adjuvant chemoradiotherapy obtained in a small randomized-controlled trial more than 15 years ago. The purpose of this article is to review the results of several trials investigating adjuvant therapy for pancreatic cancer. We will discuss recent studies of EORTC (European Organization for Research and Treatment of Cancer), ESPAC (European Study Group for Pancreatic Cancer) and others and will also focus on future alternative treatment options for pancreatic cancer.

Original language	English
Pages (from-to)	74-80
Number of pages	7
Journal	Swiss Surgery
Volume	8
Issue number	2
DOIs	https://doi.org/10.1024/1023-9332.8.2.74
State	Published - 2002
Externally published	Yes

Keywords

Adjuvant therapy
Chemotherapy
Pancreatic cancer
Radiotherapy
Surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1024/1023-9332.8.2.74

Cite this

@article{739399aa7ee5418fb1f9b174c9cf5649,

title = "Adjuvant therapy in operable pancreatic cancer",

abstract = "Adenocarcinoma of the pancreas remains a highly lethal disease with one of the worst mean survival rates of all solid malignancies. Even with improvements in surgical techniques in the last decades, the five-year survival rate of patients following resection is still under 20 percent. Various additional treatment concepts have been introduced based on encouraging results for adjuvant chemoradiotherapy obtained in a small randomized-controlled trial more than 15 years ago. The purpose of this article is to review the results of several trials investigating adjuvant therapy for pancreatic cancer. We will discuss recent studies of EORTC (European Organization for Research and Treatment of Cancer), ESPAC (European Study Group for Pancreatic Cancer) and others and will also focus on future alternative treatment options for pancreatic cancer.",

keywords = "Adjuvant therapy, Chemotherapy, Pancreatic cancer, Radiotherapy, Surgery",

author = "Wente, {M. N.} and P. B{\"u}chler and H. Friess and B{\"u}chler, {M. W.}",

year = "2002",

doi = "10.1024/1023-9332.8.2.74",

language = "English",

volume = "8",

pages = "74--80",

journal = "Swiss Surgery",

issn = "1023-9332",

publisher = "Verlag Hans Huber AG",

number = "2",

}

TY - JOUR

T1 - Adjuvant therapy in operable pancreatic cancer

AU - Wente, M. N.

AU - Büchler, P.

AU - Friess, H.

AU - Büchler, M. W.

PY - 2002

Y1 - 2002

N2 - Adenocarcinoma of the pancreas remains a highly lethal disease with one of the worst mean survival rates of all solid malignancies. Even with improvements in surgical techniques in the last decades, the five-year survival rate of patients following resection is still under 20 percent. Various additional treatment concepts have been introduced based on encouraging results for adjuvant chemoradiotherapy obtained in a small randomized-controlled trial more than 15 years ago. The purpose of this article is to review the results of several trials investigating adjuvant therapy for pancreatic cancer. We will discuss recent studies of EORTC (European Organization for Research and Treatment of Cancer), ESPAC (European Study Group for Pancreatic Cancer) and others and will also focus on future alternative treatment options for pancreatic cancer.

AB - Adenocarcinoma of the pancreas remains a highly lethal disease with one of the worst mean survival rates of all solid malignancies. Even with improvements in surgical techniques in the last decades, the five-year survival rate of patients following resection is still under 20 percent. Various additional treatment concepts have been introduced based on encouraging results for adjuvant chemoradiotherapy obtained in a small randomized-controlled trial more than 15 years ago. The purpose of this article is to review the results of several trials investigating adjuvant therapy for pancreatic cancer. We will discuss recent studies of EORTC (European Organization for Research and Treatment of Cancer), ESPAC (European Study Group for Pancreatic Cancer) and others and will also focus on future alternative treatment options for pancreatic cancer.

KW - Adjuvant therapy

KW - Chemotherapy

KW - Pancreatic cancer

KW - Radiotherapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=0036227653&partnerID=8YFLogxK

U2 - 10.1024/1023-9332.8.2.74

DO - 10.1024/1023-9332.8.2.74

M3 - Article

C2 - 12013694

AN - SCOPUS:0036227653

SN - 1023-9332

VL - 8

SP - 74

EP - 80

JO - Swiss Surgery

JF - Swiss Surgery

IS - 2

ER -

Adjuvant therapy in operable pancreatic cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this